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Abstract
Background: Hemojuvelin (HJV) is one of essential components for expression of hepcidin, a hormone which
regulates iron transport. HJV is mainly expressed in muscle and liver, and processing of HJV in both tissues is
similar. However, hepcidin is expressed in liver but not in muscle and the role of the muscle HJV is yet to be
established. Our preliminary analyses of mouse tissue HJV showed that the apparent molecular masses of HJV
peptides are different in liver (50 kDa monomer and 35 and 20 kDa heterodimer fragments) and in muscle (55 kDa
monomer and a 34 kDa possible large fragment of heterodimer). One possible explanation is glycosylation which
could lead to difference in molecular mass.
Results: We investigated glycosylation of HJV in both liver and muscle tissue from mice. PNGase F treatment
revealed that the HJV large fragments of liver and muscle were digested to peptides with similar masses, 30 and
31 kDa, respectively, and the liver 20 kDa small fragment of heterodimer was digested to 16 kDa, while the 50 kDa
liver and 55 kDa muscle monomers were reduced to 42 and 48 kDa, respectively. Endo H treatment produced
distinct digestion profiles of the large fragment: a small fraction of the 35 kDa peptide was reduced to 33 kDa in
liver, while the majority of the 34 kDa peptide was digested to 33 kDa and a very small fraction to 31 kDa in
muscle. In addition, liver HJV was found to be neuraminidase-sensitive but its muscle counterpart was
neuraminidase-resistant.
Conclusions: Our results indicate that different oligosaccharides are attached to liver and muscle HJV peptides,
which may contribute to different functions of HJV in the two tissues.
Background
Mammalian iron homeostasis is largely regulated by
hepcidin. Increased levels of hepcidin result in iron defi-
ciency while decreased expression causes iron overload.
Gene mutations affecting the gene HFE2, which encodes
HJV protein, result in the absence of hepcidin and cause
juvenile hemochromatosis [1]. The importance of HJV as
a key component of hepcidin expression has been further
underlined by studies which implicate HJV in interac-
tions with BMPs, matriptase-2, and neogenin in crucial
mechanisms of induction of hepcidin transcription in
liver [2-5]. Expression and processing of HJV protein
have been investigated extensively [6-13]. However, many
features of HJV still remain unexplained. For example,
the roles of muscle HJV are still unknown. Several HJV
peptides have been detected by immunoblotting but the
definitive mechanisms of HJV processing and details of
modification such as glycosylation have not been fully
elucidated. In addition, despite its importance, direct stu-
dies of HJV from tissues are rare.
HJV is identical to repulsive guidance molecule C
(RGMc), a member of the RGM family. It shares key
structural characteristics with RGMa and RGMb: an
N-terminal signal peptide for targeting to the endoplasmic
reticulum (ER), a potential integrin-binding RGD tri-
amino acid motif, a partial von Willebrand factor type D
domain in which an auto-cleavage site is located, and a
C-terminal GPI-anchoring domain [14]. Also two of the
three N-glycosylation sites of mouse RGMc/HJV align
with those of RGM family members. In addition, all
RGMs are known to interact with neogenin [15] and are
required for BMP signaling [16]. However, RGMc appears
to differ from the others in expression and function.
RGMa and RGMb are expressed in the developing and
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adult central nervous system [17,18], and a known func-
tion of mouse RGMa is neural tube closure [19]. RGMc/
HJV is mainly expressed in the liver, skeletal muscle, and
heart and has never been detected in the nervous system
[17]. So far its key role in hepcidin expression in liver is its
sole known function. Previously, two membrane-anchored
HJV (m-HJV), a 50-55 kDa monomer and a heterodimer
consisting of 20 and 35 kDa peptides, and soluble HJV
(s-HJV) around 30-50 kDa have been detected in cultured
cells, tissues (liver, skeletal muscle, and heart), blood, and
serum [2,6,7,9,10,20,21]. Recently, three distinct transcripts
of RGMc/HJV in muscle that vary in the length of the 5’
untranslated region have been identified [22].
Glycosylation is a common post-translational modifica-
tion. Glycoproteins participate in important biological
processes such as receptor activation, signal transduction,
and endocytosis [23]. N-glycosylation takes place at
asparagine residues of Asn-X-Ser/Thr motifs when core
glycan consisting of 14 sugars is co-translationally
attached to newly synthesized polypeptides in the lumen
of the ER: the attached glycans play a pivotal role in pro-
tein folding, oligomerization, quality control, sorting, and
transport. They are subsequently subjected to extensive
modification in the Golgi complex, where substrate
molecules are progressively modified by the full panel of
modifying enzymes to produce a wide diversity of struc-
ture [24,25]. In O-glycosylation, oligosaccharides are
attached to serine and threonine residues; O-linked gly-
cans may serve for cell signaling, prevention of protein
phosphorylation, or regulation of protein turnover [26].
Structural variations in the glycan repertoire at the cell
surface produce numerous biomarkers, some of which
correlate with differentiation, cell activation, and disease
[23]; this suggests that differently glycosylated proteins
can have different roles.
We studied HJV from mouse tissues because HJV is
located on the extracellular surface/space of the cell
membrane where it can interact with molecules on the
same cell as well as those of neighboring cells in any
direction. The surrounding environment of HJV in tis-
sues may not be duplicated in cell culture systems.
Therefore, we examined HJV in liver and muscle, com-
paring samples from HJV wild type (WT) and knock out
(KO) mice, with two N-glycosidases, PNGase F and Endo
H, and also with O-glycosidase together with neuramini-
dase, an exoglycosidase. The detected differences may
provide insights into possible different roles of HJV in
the two tissues.
Methods
Extraction and PI-PLC treatment
Hemojuvelin WT and KO mice (deletion of exon 2 of
the Hfe2 gene) were a generous gift from Prof. Silvia
Arber, Basel, Switzerland [27]. All animal experiments
were approved by the Ethics Committee of the First
Faculty of Medicine, Charles University in Prague. Tis-
sue protein was extracted with TBS (20 mM Tris pH
7.4 with 150 mM NaCl) containing 10 mM EDTA, 1%
Triton X-100, and a protease inhibitor cocktail (Roche).
Extracts were obtained by homogenizing 100 mg of tis-
sue with 500 μL of the buffer at 4°C and subsequent
centrifugation at 16,000 × g for 20 minutes at 4°C. Pro-
tein concentration was measured by Bradford reagent
(Sigma). Phosphatidylinositol-specific phospholipase C
(PI-PLC) treatment to release GPI anchor-protein com-
plex from the membrane was done by incubating 100
μL of the extract (around 5 mg of protein) with 150 mU
of PI-PLC (Sigma) and a protease inhibitor cocktail in
150 μL of 60 mM Tris-HCl pH 7.4 at 37°C for 3 hours.
The reaction mixture was centrifuged at 16,000 × g for
30 minutes at 4°C and the clear supernatant was sepa-
rated from the membrane precipitate.
Immunoaffinity purification
Immunoaffinity beads were prepared according to the
manufacturer’s instruction. At first, six μg of anti-mouse
RGM-C antibody (R &D Systems) was incubated with
25 μL suspension of magnetic beads coated with protein
G (Dynabeads Protein G, Invitrogen) and then the bound
IgG was cross-linked to the beads by Bis (sulfo succinimi-
dyl) suberate (BS3) (Sigma). PI-PLC treated samples which
contain 400 μg of protein in around 20 μL were incubated
with the immunoaffinity beads for 30 minutes with tilting
and rotating at room temperature. After washing with
TBS containing 0.1% Tween 20 (TBS/T) immunoaffinity-
purified proteins were eluted from the beads by 15 μL of
100 mM Glycine-HCl pH 2.8 after 3 minutes of incubation
and the eluates were immediately neutralized with 1 μL of
1 M Tris-HCl pH 8.8.
Glycosylation Study
Glycosidase treatment was carried out based on the
protocols of New England BioLabs. Typically, PI-PLC
treated samples containing 60 μg of protein were com-
bined with the denaturing buffer containing SDS and
DTT in 12 μl reaction mixture and then were heated at
100°C for 10 minutes. Subsequently, corresponding
reaction buffer, NP-40 if necessary, and glycosidase(s)
were added. The final reaction mixtures, 16 to 20 μL,
were incubated at 37°C for one to two hours. Peptide
N-glycosidase F was obtained from Sigma (P7367),
Endoglycosidase H (P0702), endo-a-N-acetylgalactosami-
nidase (P0733), and neuraminidase (P0720) were form
New England BioLabs.
Immunoblotting
Proteins were separated on 10% SDS-PAGE under redu-
cing or non-reducing condition and transferred to PVDF
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membrane (GE Healthcare) by electroblotting. The stan-
dard procedure using TBS/T for washing, 5% (w/v) non-
fat milk in TBS/T for blocking, 16 hours incubation at 4°C
with the primary antibody (anti-mouse RGM-C, R and D
systems; 0.3 μg/mL), and 2 hours incubation at room tem-
perature with the peroxidase-conjugated anti-goat second-
ary antibody (Jackson Immuno Research; 1:1000) was
employed. Positive signals were visualized on X-ray film
by chemiluminescence using detection reagents (Cell Sig-
naling Technology). For the loading control the same
membrane was treated, after washing with stripping buffer
(ABcam protocol), with anti-GAPDH antibody (Sigma,
G9545; 2.5 ng/mL) and subsequently with anti-rabbit sec-
ondary antibody (Jackson Immuno Research; 1:1000).
Mark 12 Unstained Standard (Invitrogen, LC5677) and
Sigma Marker wide Range (Sigma, S8445) were used to
estimate the molecular mass of protein bands.
Results
Detection of minor proteins in extract from animal tissues
by immunoblotting encounters difficulties because of non-
specific positive signals due to high contents of certain
other proteins and a high background. Therefore, an opti-
mal condition for the immunodetection of HJV using a
commercial antibody was established by analyzing extracts
from WT and KO mice in reducing and non-reducing
SDS-PAGE. The use of KO extracts enabled us to
determine non-specific positive signals and eliminate them
from consideration. Based on previous reports and
comparison of WT and KO samples, we determined HJV
peptides in tissue. Figures are representatives of more than
two experiments. The molecular masses are approxima-
tions based on two commercial standards.
Detection of tissue hemojuvelin
In liver samples (Figure 1A, 1-4), under non-reducing
conditions a thick positive band which contains single
chain monomers and heterodimers was clearly detected
around 50 kDa and under reducing conditions distinc-
tive 35 and 20 kDa bands, two fragments of the hetero-
dimer, were detected in WT but not in KO samples. In
muscle samples (Figure 1A, 5-8), many non-specific
bands appeared in both WT and KO samples and no
clear positive bands were detected under non-reducing
condition. However, a positive band at 34 kDa, possibly
the large fragment of the heterodimer, was detected
uniquely in WT but not in KO samples under reducing
conditions. Interestingly, the muscle small fragment
which is expected to be around 20 kDa was not
detected. Instead, a smudge was detected at 14-18 kDa
in WT but not in KO samples under both conditions.
In both liver and muscle samples, 50-55 kDa monomers
were not clearly detected even under reducing condi-
tions at this stage.
Figure 1 HJV in Liver and Muscle. A. Extracts containing 60 μg of protein from HJV WT and KO mice were analyzed by 10% SDS-PAGE under
non-reducing (NR) and reducing (R) conditions. Arrows indicate HJV peptides. B. Immunoaffinity-purified samples were analyzed by 10% SDS-
PAGE under non-reducing (NR) and reducing (R) conditions. HJV peptides were detected by immunoblotting.
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Immunoaffinity Purification
There may have been HJV peptides whose quantities in
the extracts were very low, and thus went undetected in
the previous blot. Therefore, in order to see a more com-
plete profile of HJV peptides in the extracts, the samples
were subjected to PI-PLC treatment, which detaches the
GPI-anchoring membrane from the protein-GPI complex
and would make HJV peptides more exposed, and subse-
quently to immunoaffinity purification. Because of cross-
linking of the bound anti-RGMc IgG to protein G on the
surface of the beads by BS3 the exposure of the cross-
linked antibody may not be uniform. Also HJV exist in
different forms. Therefore, capture of HJV peptides by
the immunoaffinity beads may not be quantitative.
In liver samples (Figure 1B, 1-4), a thick band around
50 kDa as well as a faint band around 35 kDa were
detected under non-reducing conditions, indicating the
presence of 35 kDa HJV peptides which are not the large
fragment of the heterodimer. Under reducing conditions
a single band at 50 kDa and multiple bands around
35 kDa, one of which had a more intense signal than the
others, were detected. The 20 kDa band was barely
detected. In muscle samples (Figure 1B, 5-8), thick multi-
ple bands around 50 kDa and also a very faint 35 kDa
band were detected under non-reducing conditions.
Unlike the case of liver samples, multiple bands around
50-55 kDa were detected but as with liver, multiple
bands around 35 kDa, were detected under reducing con-
ditions. The smudge was not detected. The multiple
bands detected around 35 kDa under reducing condition
indicate that the large fragment of the heterodimer in
both samples may have microheterogeneity.
Glycosidase Treatments
The revelation of a difference in the apparent molecular
mass of HJV peptides in liver and muscle and the detection
of possible microheterogeneity led us to study glycosyla-
tion in HJV. After removal of the membrane by PI-PLC
and denaturation for glycosidase treatment, 100 C for
10 minutes in buffer containing detergent and reducing
agent, the epitopes in HJV peptides appeared to be more
accessible to the antibody; thus the positive signals became
more intense, except for the 20 kDa peptide, whose posi-
tive signal became less intense after all treatments. In an
attempt to detect minor positive signals, 60 μg of protein
from each sample was analyzed by SDS-PAGE under redu-
cing conditions. Mouse HJV consists of 420 amino acids
(aa.): a signal peptide (aa. 1-32), a mature peptide (aa.
33-393), and a propeptide (aa. 394-420). There are three
putative N-glycosylation sites at aa. 111, 206, and 365 in
mature HJV. The auto-cleavage site which generates het-
erodimer is at 165-166. Therefore, the small fragment (aa.
33-165) may have one oligosaccharide branch and the
large fragment (aa. 166-393), two branches.
Peptide N-Glycosidase F
PNGase F is an N-glycosidase that removes sugar moiety
from asparagine residues at the attachment site of glyco-
proteins. The treatment provides the approximate molecu-
lar mass of naked peptides. In liver samples (Figure 2, a-d),
a 50 kDa band, a thick 35 kDa band with a faint band just
above, and a very faint 20 kDa band were detected in WT
control. After the treatment the 50 kDa monomer band
was reduced to a band around 42 kDa, and the multiple
bands around 35 kDa were digested to a thin 32 kDa and
a thick 30 kDa band. The thin 32 kDa peptide may be a
final digestion product, not an intermediate to the 30 kDa
peptide, since the two bands appeared in the same manner
after treatments with a two-fold increase of enzyme con-
centration and/or reaction time (data not shown). The
20 kDa band was reduced to a band of 16 kDa. In muscle
samples (Figure 2, e-h), non-specific signals were always
detected in both WT and KO samples; however, the mul-
tiple bands of the monomer and the large fragment were
clearly detected as thick 55 and 34 kDa bands only in WT
control. The 55 kDa band was reduced to around 48 kDa
and the 34 kDa band to 31 kDa, clearly demonstrating a
difference in size of the deglycosylation products between
liver and muscle samples.
Endoglycosidase H
Endo H cleaves mannose and oligosaccharides from N-
linked glycoproteins. This treatment provides information
on modification of the sugar moiety in the Golgi complex.
Figure 2 PNGase F treatment of Liver and Muscle HJV. PNGase
F-treated and control samples containing 60 μg of protein were
analyzed by 10% SDS-PAGE under reducing condition. HJV peptides
were detected by immunoblotting. Thick arrows indicate control
HJV peptides and thin arrows indicate digested HJV peptides.
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In liver samples (Figure 3, a-d), after treatment a thin band
appeared under both 50 and 35 kDa bands, at around 48
and 33 kDa, respectively, but the majority of both peptides
appeared unchanged, as did the 20 kDa band. In muscle
samples (Figure 3, e-h), the 55 kDa band became less
intense but its size seemed unchanged, while the 34 kDa
band was reduced to a thick 33 kDa and a very thin
31 kDa band. The profile did not change for treatment
with a two-fold increase of enzyme concentration and/or
reaction time (data not shown).
O-Glycosidase and Neuraminidase
To check whether HJV underwent another modification
besides N-glycosylation, O-glycosylation was tested by
O-glycosidase which removes O-linked disaccharides
from serine and threonine residues at the attachment
site. Neuraminidase (sialidase) is an exoglycosidase that
cleaves N-acetyl neuraminic acid residues (sialic acid)
from glycoproteins. The former needs trimming of glyco-
proteins by the latter for its enzymatic action. In liver
samples, a small size reduction of 1-2 kDa was detected
for the 50 and 35 kDa bands but not clearly so for the
20 kDa band, while in muscle samples, no change was
observed (Figure 4). Control digestion by only neuramini-
dase produced the same result for the two bands but the
20 kDa band also seemed digested, (Figure 5). Thus the
size reduction was due to neuraminidase action, not to
O-glycosidase.
Discussion
Many glycoproteins are positioned at the cell surface
and in the extracellular compartment, where cell-cell
communication is occurring among various cell types in
intact organisms [23]; HJV is one of them. Therefore, it
is appropriate to use tissue samples to study the glycosy-
lation of HJV. Our study using mouse tissue samples
revealed complex glycosylation profiles of HJV, confirm-
ing both microheterogeneity and differential glycosyla-
tion in liver and muscle.
Under non-reducing conditions a liver HJV band was
clearly detected but a muscle HJV band was barely visi-
ble, which indicates that muscle HJV peptides in the
extracts are less exposed to the antibody than their liver
counterparts. The 50-55 kDa monomer peptides of both
liver and muscle HJV were still not clearly detected even
under reducing conditions. Since HJV is a GPI-anchored
protein, exposure of its epitopes may be influenced by
interaction among HJV peptides, GPI, and the membrane
[28]. It is likely that the surrounding environments,
including GPI-anchoring, of HJV in liver and muscle are
different. Under reducing conditions the 34 kDa muscle
HJV peptide, a possible large fragment of heterodimer,
was detected, but unlike what was found in liver samples,
the small fragment was not detected. Instead, the 14-
18 kDa smudge was detected under the both conditions.
It might be that after auto-cleavage the muscle small
fragment was processed in such a way that it could no
longer form disulfide bonds and/or be degraded into
smaller peptides. It should be noted that the positive
Figure 3 Endo H treatment of Liver and Muscle HJV. Endo H-
treated and control samples containing 60 μg of proteins were
analyzed by 10% SDS-PAGE under reducing condition. HJV peptides
were detected by immunoblotting. Arrows are as in Figure 2.
Figure 4 O-Glycosidase/Neuraminidase treatment of Liver and
Muscle HJV. Glycosidase-treated and control samples containing
60 μg of preotein were analyzed by 10% SDS-PAGE under reducing
condition. HJV peptides were detected by immunoblotting. Arrows
are as in Figure 2
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signal of the liver 20 kDa small fragment became less
intense after treatments with PI-PLC and glycosidases.
Previous studies also showed its weak detection [7].
Thus, the small fragment of the heterodimer may be
unstable for detection by immunoblotting. After PI-PLC
treatment detached membranes were removed by centri-
fugation. A much larger pellet was spun down from the
liver than from the muscle samples, clearly indicating a
difference in the membrane structure for GPI anchoring
between the tissues. When the extracts were ultracentri-
fuged, 80,000 × g for 45 minutes, HJV bands were detected
only in the pellet from which the HJV peptides were
released by subsequent PI-PLC treatment [29]. Therefore,
the positive signals are of membrane-anchored HJV. It is
possible that concentrations of soluble HJV in the extracts
were too low to be detected by the immunoblotting
employed for this study.
Profiles of immunoaffinity purification (Figure 1B)
revealed not only the size differences of HJV peptides in
the two tissues, but also differences in peptide form, indi-
cating microheterogeneity of attached oligosaccharides.
Interestingly, only the liver monomer appeared differ-
ently as a single band or possible multiple bands of very
similar masses. Detection of the peptides around 35 kDa
in both samples under non-reducing condition, whose
intensity was stronger in liver than muscle, clearly indi-
cates the presence of intracellular intermediates and/or
soluble HJV in the extracts. The presence of intermediate
HJV peptides has been previously suggested [5]. Soluble
HJV have been detected in serum and blood on human
and mouse (40 and 50 kDa peptides) by immunoaffinity
purification [8] and in human serum (33 and 43 kDa pep-
tides) by immunoprecipitation [21]. The apparent size
difference of 50-55 kDa band between the reducing and
the non-reducing samples may be due to disulfide bond-
ing in the monomer under non-reducing conditions
which makes the peptide more compact and lets it move
faster in the gel. A similar observation has been reported
elsewhere [30]. It is puzzling that although immunoaffi-
nity purification indicates that 34 kDa muscle large frag-
ments are in heterodimer form under non-reducing
conditions (Figure 1B, 5-8), corresponding small frag-
ments were not detected under reducing conditions
(Figure 1A, 7).
The heterodimer is an auto-cleavage product from a
mature protein [14], thus both the monomer and the het-
erodimer possess three N-glycosylation sites. But they are
differently processed as their final forms on the cell sur-
face are different. Therefore, it is possible that mature
HJV peptides which eventually convert into heterodimers
are differently glycosylated from those that remain
monomers. The majority of the muscle monomer was
reduced to around 48 kDa and the liver counterpart to
around 42 kDa by PNGase F treatment, which also sug-
gests the presence of other modifications, including other
types of N- or O- glycosylation, and/or processing, e.g.
splicing, that produce muscle HJV with a higher apparent
molecular mass. The mass difference may also be due to
variation in the composition and size of the GPI anchor.
It is clear that the large fragment of the heterodimer has
different oligosaccharide branches in liver and muscle
since the 35 kDa peptide of liver HJV was reduced to
30 kDa, while its 34 kDa muscle counterpart was reduced
to 31 kDa. PNGase F treatment removes nearly all types
of N-linked oligosaccharides from glycoproteins; it there-
fore provides approximate molecular mass of proteins
based on amino acid residues. The theoretical molecular
mass of the large fragment is approximately 25 kDa
Figure 5 Neuraminidase digestion of Liver HJV. Aliquots
containing 60 μg of protein from control (1), treated only with
neuraminidase (2), and treated with neuraminidase and O-
glycosidase (3) samples were analyzed by 10% SDS-PAGE under
reducing condition. HJV peptides were detected by
immunoblotting. Arrows are as in Figure 2
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(aa. 166-393), which also indicates possible involvement
of other modifications. The 20 kDa liver peptide was
reduced to around 16 kDa, which corresponds well with
a theoretical molecular mass of 14 kDa for the small frag-
ment (aa. 33-165).
Glycoproteins that undergo modifications in the Golgi
complex may become Endo H-resistant. Therefore, the
appearance of a slightly smaller band under both the
monomer and the large fragment in the liver samples
suggests that there is a small fraction of Endo H-sensitive
HJV whereas the majority is Endo H-resistant. On the
other hand, all of the muscle large fragments were
digested, and thus are Endo H-sensitive, which is expli-
citly different from what was seen for liver. The detection
of the very faint 31 kDa band in muscle samples indicates
that a small fraction of the fragment undergoes very dif-
ferent modification from the rest. It is clear that microhe-
terogeneity exists in the large fragment in which the
second and third N-glycosylation sites are located in both
tissues. Any small size reduction of the 55 kDa muscle
monomer may not be clearly detected due to the concen-
tration of acrylamide (10%) in the gel, which is suitable
for separation of 20-40 kDa peptides. The finding that
the liver HJV is neuraminidase-sensitive while its muscle
counterpart is resistant also points to differential modifi-
cation in the Golgi complex in the two tissues. Different
size reductions by deglycosylation have been reported for
cultured cells, depending on cell type [7,13,30]. The level
of mRNA of RGMc/HJV in skeletal muscle in mouse was
found to be much higher than that in liver [19]. However,
detection of HJV by immunoblotting for liver and muscle
samples in our study appeared comparable, thus HJV
level in the total protein composition in both tissues is
similar, indicating a difference in post-transcriptional
control between the two tissues. A recent report that
liver hepcidin expression is not affected by loss of HJV in
skeletal muscle [31] indicates different roles of HJV from
liver and muscle, respectively, which might well be desig-
nated by differential glycosylation.
It should be noted that although the first and third
N-glycosylation sites (aa. 111 and 365, respectively) per-
fectly align among the mouse RGM family, the second
site of HJV/RGMc (aa. 206) does not align with that of
RGMa in the conservative von Willebrand factor type D
domain (aa. 154-216), and RGMb does not have a N-
glycosylation site in the central region. To our knowl-
edge, the unique second N-glycosylation site and the
proprotein convertase cleavage site set HJV/RGMc apart
from the other RGM members. According to a structural
model of RGM protein [32], the second N-glycosylation
site lies near the central core and the third site is located
at the far end of the structure. Therefore, it is possible
that the sugar moiety attached to the second site influ-
ences the conformation of the peptide and its interaction
with molecules in the vicinity. It has been reported that
the induction of hepcidin expression only requires a
small amount of HJV [33]. Therefore, it is tempting to
speculate that only a small fraction of HJV with distinct
oligosaccharide branches participates in the signaling
pathway of hepcidin expression.
Conclusions
HJV peptides of both liver and muscle were detected as
multiple bands and glycosidase treatments confirmed
microheterogeneity of HJV in both tissues. In addition, the
large fragment of the heterodimer was found to have dif-
ferent oligosaccharide branches in liver vs. muscle. There-
fore, since it is known that the second N-glycosylation site
in the large fragment is unique to RMGc/HJV among the
RMG family, glycosylation at the second site may be a key
to elucidating distinct functions of RGMc/HJV in the two
tissues, as well as in the RGM family more broadly.
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